Zimmer Biomet (NYSE:ZBH) Rating Increased to Hold at BMO Capital Markets

BMO Capital Markets upgraded shares of Zimmer Biomet (NYSE:ZBH) to a hold rating in a research note issued to investors on Wednesday,Zacks.com reports.

ZBH has been the topic of several other research reports. Wells Fargo & Company dropped their price target on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 29th. Canaccord Genuity Group set a $83.00 price objective on Zimmer Biomet in a research note on Wednesday, April 29th. JPMorgan Chase & Co. decreased their target price on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a report on Wednesday, April 29th. Stifel Nicolaus cut their price target on Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a report on Wednesday, April 29th. Finally, Leerink Partners assumed coverage on Zimmer Biomet in a research report on Monday, April 13th. They issued a “hold” rating and a $101.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and a consensus target price of $102.33.

Zimmer Biomet Price Performance

NYSE ZBH opened at $89.24 on Wednesday. Zimmer Biomet has a 52 week low of $79.12 and a 52 week high of $108.29. The firm has a market capitalization of $17.26 billion, a P/E ratio of 23.18, a PEG ratio of 2.58 and a beta of 0.46. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. The company has a 50-day moving average price of $86.03 and a 200-day moving average price of $89.75.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The company had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm’s revenue was up 9.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities research analysts anticipate that Zimmer Biomet will post 8.48 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s payout ratio is presently 24.94%.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.28% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Valeo Financial Advisors LLC raised its position in shares of Zimmer Biomet by 1.6% during the second quarter. Valeo Financial Advisors LLC now owns 11,176 shares of the medical equipment provider’s stock valued at $962,000 after buying an additional 175 shares during the last quarter. Wilsey Asset Management Inc. lifted its holdings in shares of Zimmer Biomet by 4.7% in the second quarter. Wilsey Asset Management Inc. now owns 421,867 shares of the medical equipment provider’s stock worth $36,318,000 after buying an additional 18,883 shares in the last quarter. Elevation Wealth Partners LLC boosted its position in shares of Zimmer Biomet by 145.9% during the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 229 shares during the last quarter. Czech National Bank grew its stake in Zimmer Biomet by 2.0% during the second quarter. Czech National Bank now owns 55,067 shares of the medical equipment provider’s stock valued at $4,741,000 after acquiring an additional 1,093 shares in the last quarter. Finally, PensionDanmark Pensionsforsikringsaktieselskab grew its stake in Zimmer Biomet by 10.0% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 35,168 shares of the medical equipment provider’s stock valued at $3,028,000 after acquiring an additional 3,200 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.